MeVis Medical Solutions AG

Transaction in Own Shares • Mar 31, 2009

News Details

Ad-hoc | 31 March 2009 16:37

MeVis Medical Solutions AG: termination of stock buy-back program as scheduled

MeVis Medical Solutions AG / Share Buyback

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Bremen, March 31, 2009 - Today Bremen-based MeVis Medical Solutions AG
[ISIN: DE000A0LBFE4], a specialist in disease-oriented software products
for image-based medicine, terminated its stock buy-back program as
scheduled.

Under a resolution passed at the annual general meeting on July 9, 2008,
the Company is authorized to buy back up to 10 percent of its own current
share capital in accordance with Section 71 (1) Sentence 1 No. 8 of the
German Stock Corporations Act.

The Executive Board decided on November 4, 2008 to buy back a further
volume of up to 91,000 of the Company's own shares via the stock market
until March 31, 2009. Under this stock repurchase program, the Company has
acquired 33,682 of its own shares as of today's date resulting in total
expenses of EUR 1.16 million. All the stock was bought via the Xetra
electronic trading platform and on the floor of the Frankfurt stock
exchange via M.M. Warburg & CO.

At the launching date of this stock buy-back program the Company already
held 91,000 of its own shares in treasury, representing 5 percent of its
share capital. As a result, MeVis Medical Solutions AG's treasury stock
currently amounts to a total of 122,850 shares, representing 6.75 percent
of its current share capital. On November 21, 2008 the Company used 1,832
of its own shares for the acquisition of intellectual property in the area
of virtual colonoscopy.

By repurchasing its own shares, the Company intends to gain additional
strategic scope in the event of acquisitions, the purchase of intellectual
property, investments and similar transactions aimed at further
implementing its growth strategy. Unless these transactions can be realized
in the foreseeable future, the treasury stock held by the Company can also
be redeemed. The Executive Board regards a 6.75 percent share appropriate
to realize the strategic goals pursued with the buy-back program.

Detailed information on the progress of the stock buy-back program to date
is published in accordance with Art. 4 (3) and (4) of Commission Regulation
(EC) No 2273/2003 of December 22, 2003 as regards exemptions for buy-back
programs and stabilization of financial instruments in connection with
Article 20 (1) of Council Directive 93/22/EEC of May 10, 1993 on investment
services in the securities field is available at the Company's website at
www.mevis.de.
31.03.2009 Financial News transmitted by DGAP

---

Language: English
Issuer: MeVis Medical Solutions AG
Universitätsallee 29
28359 Bremen
Deutschland
Phone: +49 421 330 74-0
Fax: +49 421 330 74-50
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, München, Düsseldorf, Stuttgart

End of News DGAP News-Service

---